Evidence map›Paper›PMID 31557240›Full record

ArticlePloS one2019

Prediction of lymphovascular space invasion in endometrial cancer using the 55-gene signature selected by DNA microarray analysis.

Takafumi Watanabe, Reiko Honma, Manabu Kojima, Shinji Nomura, Shigenori Furukawa, Shu Soeda, Shinya Watanabe, Keiya Fujimori

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Takafumi WatanabeDepartment of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan.ORCID 0000-0001-6974-0312
Reiko HonmaNippon Gene Co., Ltd., Chiyoda, Tokyo, Japan.
Manabu KojimaDepartment of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Shinji NomuraDepartment of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Shigenori FurukawaDepartment of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Shu SoedaDepartment of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Shinya WatanabeMedical-Industrial Translational Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
Keiya FujimoriDepartment of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphovascular space invasion (LVSI) is considered to be the beginning of lymphogenous and hematogenous metastases. It is strongly related to dissemination, and therefore could be a valuable predictive sign of lymph node metastases and distant spread. Recently, the presence of LVSI in endometrial cancer (EC) has been shown to be an independent prognostic factor. The preoperative diagnosis of LVSI by pathological examination is difficult and LVSI is detected after surgery. The aim of the current study was to explore candidate genes as potential diagnostic biomarkers and determine whether they are predictors of LVSI in patients with EC. A total of 88 surgical specimens obtained from EC patients who had undergone surgical resection at Fukushima Medical University Hospital between 2010 and 2015 were analyzed using DNA microarray. LVSI was significantly associated with poor prognostic factors in EC such as higher tumor grade, lymph node metastasis, deep myometrium invasion, advanced stage and recurrence. Fifty-five candidate genes were significantly differentially expressed between 26 LVSI-positive and 62 LVSI-negative samples. All 88 samples were divided into two groups according to hierarchical clustering of 55 genes. Regarding diagnostic accuracy, sensitivity and negative predictive value were both high (92% and 95%, respectively); further, specificity and positive predictive value were both moderate (63% and 71%, respectively). Our data suggests that the 55-gene signature could contribute to predicting LVSI in EC, and provide clinically important information for better management. The molecular signatures of 55 genes may be also useful for understanding the underlying mechanism of LVSI.

Indexed as

AdultAgedBiomarkers, TumorEndometrial NeoplasmsEndometriumFeasibility StudiesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMiddle AgedNeoplasm InvasivenessOligonucleotide Array Sequence AnalysisPrognosisRetrospective StudiesBiomarkers, Tumor

Identifiers

PMID31557240
PMCPMC6762169
OpenAlexW2976248986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.